Toll Free: 1-888-928-9744
Published: Nov, 2014 | Pages:
124 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Critical Limb Ischemia - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Critical Limb Ischemia - Pipeline Review, H2 2014', provides an overview of the Critical Limb Ischemia's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Critical Limb Ischemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Critical Limb Ischemia and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Critical Limb Ischemia - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Critical Limb Ischemia and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Critical Limb Ischemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Critical Limb Ischemia pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Critical Limb Ischemia - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Critical Limb Ischemia pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 6 List of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 Critical Limb Ischemia Overview 9 Therapeutics Development 10 Pipeline Products for Critical Limb Ischemia - Overview 10 Pipeline Products for Critical Limb Ischemia - Comparative Analysis 11 Critical Limb Ischemia - Therapeutics under Development by Companies 12 Critical Limb Ischemia - Therapeutics under Investigation by Universities/Institutes 14 Critical Limb Ischemia - Pipeline Products Glance 15 Late Stage Products 15 Clinical Stage Products 16 Early Stage Products 17 Unknown Stage Products 18 Critical Limb Ischemia - Products under Development by Companies 19 Critical Limb Ischemia - Products under Investigation by Universities/Institutes 20 Critical Limb Ischemia - Companies Involved in Therapeutics Development 21 Aastrom Biosciences, Inc. 21 AnGes MG, Inc. 22 Apceth GmbH & Co. KG 23 Athersys, Inc. 24 Hemostemix Ltd 25 Human Stem Cells Institute 26 Juventas Therapeutics, Inc. 27 Kasiak Research Pvt. Ltd. 28 Multi Gene Vascular Systems Ltd 29 NeoStem, Inc. 30 Nuo Therapeutics, Inc. 31 Pharmicell Co., Ltd. 32 Pluristem Therapeutics Inc. 33 ReNeuron Group plc 34 Stempeutics Research Private Limited 35 TikoMed AB 36 ViroMed Co., Ltd. 37 Critical Limb Ischemia - Therapeutics Assessment 38 Assessment by Monotherapy Products 38 Assessment by Target 39 Assessment by Mechanism of Action 41 Assessment by Route of Administration 43 Assessment by Molecule Type 45 Drug Profiles 47 ACP-01 - Drug Profile 47 Product Description 47 Mechanism of Action 47 R&D Progress 47 ALD-301 - Drug Profile 49 Product Description 49 Mechanism of Action 49 R&D Progress 49 Alecmestencel-T - Drug Profile 51 Product Description 51 Mechanism of Action 51 R&D Progress 51 AMR-001 - Drug Profile 52 Product Description 52 Mechanism of Action 52 R&D Progress 52 ASCT-01 - Drug Profile 54 Product Description 54 Mechanism of Action 54 R&D Progress 54 beperminogene perplasmid - Drug Profile 55 Product Description 55 Mechanism of Action 55 R&D Progress 55 Cell Therapy for Critical Limb Ischemia - Drug Profile 58 Product Description 58 Mechanism of Action 58 R&D Progress 58 Cellgram for Severe Lower Limb Ischemia - Drug Profile 59 Product Description 59 Mechanism of Action 59 R&D Progress 59 Gene Therapy to Activate Vascular Endothelial Growth Factor for Cardiovascular Diseases - Drug Profile 60 Product Description 60 Mechanism of Action 60 R&D Progress 60 ixmyelocel-T - Drug Profile 61 Product Description 61 Mechanism of Action 61 R&D Progress 61 JVS-100 - Drug Profile 64 Product Description 64 Mechanism of Action 64 R&D Progress 64 MultiGeneAngio - Drug Profile 66 Product Description 66 Mechanism of Action 66 R&D Progress 66 MultiStem - Drug Profile 68 Product Description 68 Mechanism of Action 68 R&D Progress 68 Protein for Myocardial Infarction and Critical Limb Ischemia - Drug Profile 71 Product Description 71 Mechanism of Action 71 R&D Progress 71 Recombinant Protein for Critical Limb Ischemia - Drug Profile 72 Product Description 72 Mechanism of Action 72 R&D Progress 72 Refacell-CLI - Drug Profile 73 Product Description 73 Mechanism of Action 73 R&D Progress 73 ReN-009 - Drug Profile 74 Product Description 74 Mechanism of Action 74 R&D Progress 74 Stem Cell Therapy for Cardiovascular Diseases - Drug Profile 75 Product Description 75 Mechanism of Action 75 R&D Progress 75 Stem Cell Therapy for Critical Limb Ischemia - Drug Profile 77 Product Description 77 Mechanism of Action 77 R&D Progress 77 Stem Cell Therapy for Critical Limb Ischemia - Drug Profile 78 Product Description 78 Mechanism of Action 78 R&D Progress 78 Stem Cell Therapy for Critical Limb Ischemia - Drug Profile 79 Product Description 79 Mechanism of Action 79 R&D Progress 79 Stem Cell Therapy to Activate VEGF for Critical Limb Ischemia - Drug Profile 80 Product Description 80 Mechanism of Action 80 R&D Progress 80 Stempeucel - Drug Profile 81 Product Description 81 Mechanism of Action 81 R&D Progress 81 Stromal Cell Therapy for Critical Limb Ischemia - Drug Profile 84 Product Description 84 Mechanism of Action 84 R&D Progress 84 TM-700 - Drug Profile 85 Product Description 85 Mechanism of Action 85 R&D Progress 85 VM-202 - Drug Profile 86 Product Description 86 Mechanism of Action 86 R&D Progress 86 Critical Limb Ischemia - Recent Pipeline Updates 88 Critical Limb Ischemia - Dormant Projects 114 Critical Limb Ischemia - Discontinued Products 115 Critical Limb Ischemia - Product Development Milestones 116 Featured News & Press Releases 116 Nov 18, 2014: Juventas Therapeutics Presents Phase II Data at AHA Scientific Sessions That Shows JVS-100 is Safe, Potentially Effective in Patients with Critical Limb Ischemia 116 Oct 05, 2014: AnGes Starts Global Phase III Clinical Trials of Collategene for Critical Limb Ischemia 117 Jun 25, 2014: Hemostemix Advances Clinical Trial Preparation 117 Apr 22, 2014: Hemostemix Announces its Second US Patent 118 Dec 19, 2013: Aastrom Biosciences Granted Composition-of-Matter Patent for Ixmyelocel-T in Australia 118 Apr 10, 2013: Athersys Announces Publication Of Study Results Demonstrating Relevance Of MultiStem For Autoimmune Disease, Transplantation And Vascular Disease 119 Mar 27, 2013: Aastrom Biosciences Announces Strategic Change In R&D Programs To Focus On Dilated Cardiomyopathy And Other Rare Disease Indications 120 Mar 26, 2013: ReNeuron Receives Regulatory And Ethical Approvals To Commence Clinical Trial In UK With Stem Cell Therapy Candidate For Critical Limb Ischaemia 120 Mar 11, 2013: ReNeuron Wins �0.4m Grant From UK Biomedical Catalyst To Pursue Further Development Of ReN009 Stem Cell Therapy Candidate 121 Mar 04, 2013: AnGes Group Receives FDA Approval For Revised Special Protocol Assessment For Collategene Phase III Clinical Trial 122 Appendix 123 Methodology 123 Coverage 123 Secondary Research 123 Primary Research 123 Expert Panel Validation 123 Contact Us 124 Disclaimer 124
List of Tables Number of Products under Development for Critical Limb Ischemia, H2 2014 10 Number of Products under Development for Critical Limb Ischemia - Comparative Analysis, H2 2014 11 Number of Products under Development by Companies, H2 2014 13 Number of Products under Investigation by Universities/Institutes, H2 2014 14 Comparative Analysis by Late Stage Development, H2 2014 15 Comparative Analysis by Clinical Stage Development, H2 2014 16 Comparative Analysis by Early Stage Development, H2 2014 17 Comparative Analysis by Unknown Stage Development, H2 2014 18 Products under Development by Companies, H2 2014 19 Products under Investigation by Universities/Institutes, H2 2014 20 Critical Limb Ischemia - Pipeline by Aastrom Biosciences, Inc., H2 2014 21 Critical Limb Ischemia - Pipeline by AnGes MG, Inc., H2 2014 22 Critical Limb Ischemia - Pipeline by Apceth GmbH & Co. KG, H2 2014 23 Critical Limb Ischemia - Pipeline by Athersys, Inc., H2 2014 24 Critical Limb Ischemia - Pipeline by Hemostemix Ltd, H2 2014 25 Critical Limb Ischemia - Pipeline by Human Stem Cells Institute, H2 2014 26 Critical Limb Ischemia - Pipeline by Juventas Therapeutics, Inc., H2 2014 27 Critical Limb Ischemia - Pipeline by Kasiak Research Pvt. Ltd., H2 2014 28 Critical Limb Ischemia - Pipeline by Multi Gene Vascular Systems Ltd, H2 2014 29 Critical Limb Ischemia - Pipeline by NeoStem, Inc., H2 2014 30 Critical Limb Ischemia - Pipeline by Nuo Therapeutics, Inc., H2 2014 31 Critical Limb Ischemia - Pipeline by Pharmicell Co., Ltd., H2 2014 32 Critical Limb Ischemia - Pipeline by Pluristem Therapeutics Inc., H2 2014 33 Critical Limb Ischemia - Pipeline by ReNeuron Group plc, H2 2014 34 Critical Limb Ischemia - Pipeline by Stempeutics Research Private Limited, H2 2014 35 Critical Limb Ischemia - Pipeline by TikoMed AB, H2 2014 36 Critical Limb Ischemia - Pipeline by ViroMed Co., Ltd., H2 2014 37 Assessment by Monotherapy Products, H2 2014 38 Number of Products by Stage and Target, H2 2014 40 Number of Products by Stage and Mechanism of Action, H2 2014 42 Number of Products by Stage and Route of Administration, H2 2014 44 Number of Products by Stage and Molecule Type, H2 2014 46 Critical Limb Ischemia Therapeutics - Recent Pipeline Updates, H2 2014 88 Critical Limb Ischemia - Dormant Projects, H2 2014 114 Critical Limb Ischemia - Discontinued Products, H2 2014 115
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.